Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option

被引：6
|
作者：
Passaro, Antonio [1 ]
de Marinis, Filippo [1 ]
机构：
[1] European Inst Oncol, IEO, Div Thorac Oncol, Via G Ripamonti 435, I-20141 Milan, Italy
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2018年 / 7卷
关键词：
1ST-LINE TREATMENT; OPEN-LABEL; PHASE-III; ADENOCARCINOMA; GEFITINIB; AFATINIB; CHEMOTHERAPY; MULTICENTER; ERLOTINIB;
D O I：
10.21037/tlcr.2018.02.09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S100 / S102
页数：3
相关论文
共 50 条
  • [1] Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints
    Passaro, Antonio
    de Marinis, Filippo
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S334 - S338
  • [2] Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network meta-analysis
    Zhang, Yaxiong
    Sheng, Jin
    Yang, Yunpeng
    Fang, Wenfeng
    Kang, Shiyang
    He, Yang
    Hong, Shaodong
    Zhan, Jianhua
    Zhao, Yuanyuan
    Xue, Cong
    Ma, Yuxiang
    Zhou, Ting
    Ma, Shuxiang
    Gao, Fangfang
    Qin, Tao
    Hu, Zhihuang
    Tian, Ying
    Hou, Xue
    Huang, Yan
    Zhou, Ningning
    Zhao, Hongyun
    Zhang, Li
    ONCOTARGET, 2016, 7 (15) : 20093 - 20108
  • [3] Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?
    Watanabe, Satomi
    Hayashi, Hidetoshi
    Nakagawa, Kazuhiko
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (11)
  • [4] Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group
    Sonehara, Kei
    Kobayashi, Takashi
    Tateishi, Kazunari
    Morozumi, Nobutoshi
    Yoshiike, Fumiaki
    Hachiya, Tsutomu
    Ono, Yasushi
    Takasuna, Keiichirou
    Agatsuma, Toshihiko
    Masubuchi, Takeshi
    Matsuo, Akemi
    Tanaka, Hozumi
    Morikawa, Akio
    Hanaoka, Masayuki
    Koizumi, Tomonobu
    THORACIC CANCER, 2019, 10 (05) : 1078 - 1085
  • [5] AFATINIB FOR THE TREATMENT OF PATIENTS WITH EGFR-POSITIVE NON-SMALL CELL LUNG CANCER
    Bowles, D. W.
    Weickhardt, A.
    Jimeno, A.
    DRUGS OF TODAY, 2013, 49 (09) : 523 - 535
  • [6] Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer
    Reungwetwattana, Thanyanan
    Rohatgi, Nitesh
    Mok, Tony S.
    Prabhash, Kumar
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (03): : 161 - 171
  • [7] Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?
    Roviello, Giandomenico
    Zanotti, Laura
    Cappelletti, Maria Rosa
    Gobbi, Angela
    Dester, Martina
    Paganini, Giovanni
    Pacifico, Chiara
    Generali, Daniele
    Roudi, Raheleh
    CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 18 (01) : 15 - 20
  • [8] From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study)
    Pasello, Giulia
    Vicario, Giovanni
    Zustovich, Fable
    Oniga, Francesco
    Gori, Stefania
    Rosetti, Francesco
    Bonetti, Andrea
    Favaretto, Adolfo
    Toso, Silvia
    Redelotti, Roberta
    Santo, Antonio
    Bernardi, Daniele
    Giovanis, Petros
    Oliani, Cristina
    Calvetti, Lorenzo
    Gatti, Carlo
    Palazzolo, Giovanni
    Baretta, Zora
    Bortolami, Alberto
    Bonanno, Laura
    Basso, Marco
    Menis, Jessica
    Corte, Donatella Da
    Frega, Stefano
    Guarneri, Valentina
    Conte, PierFranco
    ONCOLOGIST, 2019, 24 (06) : E318 - E326
  • [9] Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non-small cell lung cancer patients
    Tan, Xueyun
    Wang, Sufei
    Xia, Hui
    Chen, Hebing
    Xu, Juanjuan
    Meng, Daquan
    Wang, Zhihui
    Li, Yan
    Yang, Lian
    Jin, Yang
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (03) : 463 - 472
  • [10] Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations
    Wells, Leah
    Qin, Angel
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (12) : 1978 - 1993
12345